Androcur Effects on Quality of Life
Androcur is an antiandrogenic drug, which blocks the action of male sex hormones. Androcur is used for treatment of advanced prostate cancer. This study investigates the effect of Androcur on quality of life of prostate cancer patients who are taking the drug for 12 months
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Measure of Androcur Effects on Quality of Life at Prostate Cancer Patients|
- Quality of life change measured by SF-35 questionnaire [ Time Frame: Baseline, after 3, 6 and 12 month ] [ Designated as safety issue: No ]
|Study Start Date:||June 2008|
|Study Completion Date:||January 2010|
|Primary Completion Date:||January 2010 (Final data collection date for primary outcome measure)|
Drug: Cyproterone acetate (Androcur)
The study drug will be administered either as monotherapy or in combination with other interventions (surgical castration or LHRH analogue treatment).
Daily dosage as monotherapy: 200-300 mg cyproterone acetate. Daily dosage following surgical castration: 100-200 mg cyproterone acetate. Daily dosage in combination with an LHRH-analogue: 100-200 mg cyproterone acetate.
Administration period: 12 months.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00908674
|Many Locations, Hungary|
|Study Director:||Bayer Study Director||Bayer|